Genome Therapeutics Corporation

Genome Therapeutics Corporation was an early biotechnology company whose work connected genomic research with commercial pharmaceutical and biomedical applications. The business began in 1961 as Collaborative Research Inc., founded by Orrie M. Friedman. It initially operated in the broader field of biological and biomedical research before developing a stronger identity around molecular genetics and genome analysis. A major turning point came under the scientific leadership of Helen Donis-Keller. Using internal company funding, the organization produced one of the first linkage maps covering the whole human genome in the mid-1980s. At a time when comprehensive human-genome mapping was still a technically demanding and relatively new undertaking, this work helped establish the company as a participant in the emerging genomics industry. Linkage maps were important research tools because they helped scientists locate genes associated with inherited traits and diseases, even before complete DNA sequencing became practical. The company later adopted the Genome Therapeutics name, reflecting its emphasis on applying genomic information to therapeutic research. Its activities included work on infectious organisms and inherited diseases. Asthma was among the heritable or disease-related areas associated with its research efforts, although the available reference material does not provide a complete list of development programs, products, or clinical outcomes. In 1994, Genome Therapeutics completed what the reference material describes as the first commercial genome sequence: the genome of Helicobacter pylori, the bacterium associated with peptic ulcers. This project represented a significant shift in the commercial role of genome sequencing. Rather than treating sequencing only as an academic or publicly funded activity, the company used genomic information as a transactionally valuable research asset. Rights to the H. pylori genome were sold to Astra AB of Sweden for $22 million, and the company entered into a similar arrangement with Schering-Plough. These transactions demonstrated the potential value of pathogen-genome information to pharmaceutical companies seeking targets, diagnostics, and therapeutic opportunities. Genome Therapeutics eventually expanded or reorganized its technology activities. In 2004, the company changed its name to Oscient Pharmaceuticals, marking a shift away from the Genome Therapeutics corporate identity and toward a pharmaceutical-focused business. Its sequencing division combined with Agencourt Bioscience. Agencourt subsequently spun out Agencourt Personal Genomics, which was acquired by Applied Biosystems, commonly abbreviated ABI, for $120 million in 2007. The available sources do not establish Genome Therapeutics as an independent active brand after the 2004 name change, so it is treated here as defunct under its original identity.

Genome Therapeutics Corporation originated in 1961 as Collaborative Research Inc., founded by Orrie M. Friedman. The company was part of the early biotechnology and biomedical-research sector, later developing expertise in molecular genetics and genome analysis. During the 1980s, under the scientific leadership of Helen Donis-Keller, the organization used internal funds to produce one of the first linkage maps of the whole human genome. The achievement placed the company among the early commercial participants in large-scale human-genome research. Linkage mapping provided a way to associate genetic markers with inherited traits and diseases before complete genome sequencing was widely available. The organization subsequently changed its name to Genome Therapeutics. Its research portfolio extended beyond human genetics to infectious organisms and disease-related applications, including work connected with asthma. The company’s most commercially notable project was its sequencing of Helicobacter pylori, the bacterium associated with peptic ulcers. Completed in 1994, the project was described as the first commercial genome sequence. Genome Therapeutics sold rights to the resulting genome information to Astra AB of Sweden for $22 million and reached a similar type of arrangement with Schering-Plough. In 2004, the company changed its name to Oscient Pharmaceuticals. At the same time, its sequencing division joined Agencourt Bioscience, separating that genomics activity from the renamed pharmaceutical business. Agencourt later spun out Agencourt Personal Genomics, which Applied Biosystems acquired for $120 million in 2007. These later corporate developments marked the dispersal of the assets and activities associated with Genome Therapeutics. The original Genome Therapeutics brand therefore no longer represents an independent active company.

• 2007

  Applied Biosystems acquires Agencourt Personal Genomics

  [1]Genome Therapeutics Corporationen.wikipedia.org

  Agencourt Personal Genomics, spun out from the Agencourt sequencing organization, was acquired by Applied Biosystems.

• 2004

  Corporate name changes to Oscient Pharmaceuticals

  [1]Genome Therapeutics Corporationen.wikipedia.org

  The Genome Therapeutics name was replaced by Oscient Pharmaceuticals, while the sequencing division joined Agencourt Bioscience.

• 1994

  Commercial sequencing of Helicobacter pylori

  [1]Genome Therapeutics Corporationen.wikipedia.org

  Genome Therapeutics produced the first commercial genome sequence, covering Helicobacter pylori, a pathogen associated with peptic ulcers.

• 1980

  Early whole-human-genome linkage map

  [1]Genome Therapeutics Corporationen.wikipedia.org

  Under Helen Donis-Keller's scientific leadership, the company produced one of the first linkage maps of the whole human genome during the mid-1980s.

• 1961

  Collaborative Research Inc. is founded

  [1]Genome Therapeutics Corporationen.wikipedia.org

  Orrie M. Friedman founded the company under the name Collaborative Research Inc.

An early genomics and biotechnology company positioned at the intersection of genome mapping, commercial sequencing, infectious-disease research, and pharmaceutical discovery.

• Genomic research

  Human genome linkage maps

  Genome Therapeutics produced one of the first linkage maps covering the whole human genome in the mid-1980s. The work used genetic markers to help locate genomic regions associated with inherited traits and disease, contributing to the early commercial development of human-genetics research.

• Commercial genome sequencing · 1994

  Helicobacter pylori genome sequence

  Completed in 1994, this sequencing project analyzed Helicobacter pylori, the bacterium associated with peptic ulcers. The resulting genomic information became a commercial asset, with rights sold to Astra AB and a similar arrangement made with Schering-Plough.

• Therapeutic research

  Infectious-disease and inherited-disease research

  The company applied genomic methods to infectious organisms and heritable diseases. Asthma is specifically identified in the available reference material as one area of disease-related research, but detailed product names and clinical-development outcomes are not documented there.

• 2004

  Rename the company as Oscient PharmaceuticalsStrategy

  Background

  The company moved away from the Genome Therapeutics identity and reorganized its activities around a pharmaceutical business.

  Action taken

  Genome Therapeutics changed its name to Oscient Pharmaceuticals, while its sequencing division joined Agencourt Bioscience.

  Aftermath

  The change ended Genome Therapeutics as the operating corporate identity and separated its sequencing activities from the renamed pharmaceutical company.

  Source

• 1994

  Commercialize the Helicobacter pylori genome sequenceProduct launch

  Background

  Genome Therapeutics completed sequencing of Helicobacter pylori at a time when commercial genome information was an emerging biotechnology asset.

  Action taken

  The company produced the genome sequence and licensed or sold associated rights to pharmaceutical companies, including Astra AB and Schering-Plough.

  Aftermath

  The Astra AB transaction was reported at $22 million and demonstrated the commercial value that pharmaceutical companies placed on pathogen-genome information.

  Reported transaction value for rights to the Helicobacter pylori genome. $22 million (1994)

  Source

1. 1Genome Therapeutics Corporationen.wikipedia.org